[{"address1": "321 Harrison Avenue", "address2": "11th Floor, Suite 1", "city": "Boston", "state": "MA", "zip": "02118", "country": "United States", "phone": "617 453 3596", "website": "https://www.pyxisoncology.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.", "fullTimeEmployees": 44, "companyOfficers": [{"maxAge": 1, "name": "Dr. Lara S. Sullivan M.D., MBA", "title": "CEO, President, Chief Medical Officer & Director", "fiscalYear": 2024, "totalPay": 1057225, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jitendra  Wadhane C.A., CPA", "age": 44, "title": "Chief Accounting Officer, Senior VP of Finance, Corporate Controller & Principal Financial Officer", "yearBorn": 1980, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Balu N. Balasubramanian Ph.D.", "title": "Interim Chief Technology Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jan  Pinkas Ph.D.", "title": "Chief Scientific Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Charles T. Gombar Ph.D.", "title": "Senior Vice President of Portfolio & Program Management", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Stephen T. Worsley MBA", "age": 60, "title": "Senior VP & Chief Business Officer", "yearBorn": 1964, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael  Bui", "title": "Head of Global Regulatory Affairs", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Supriya  Roth Ph.D.", "title": "Head of Commercial Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Shui  He Ph.D.", "title": "Head of Biometrics", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Hongwei  Wang M.D., Ph.D.", "title": "Head of ADC Development & Clinical Strategy", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 9, "compensationRisk": 10, "shareHolderRightsRisk": 9, "overallRisk": 10, "governanceEpochDate": 1756684800, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.86, "open": 1.84, "dayLow": 1.76, "dayHigh": 1.92, "regularMarketPreviousClose": 1.86, "regularMarketOpen": 1.84, "regularMarketDayLow": 1.76, "regularMarketDayHigh": 1.92, "payoutRatio": 0.0, "beta": 1.147, "forwardPE": -1.5294118, "volume": 723147, "regularMarketVolume": 723147, "averageVolume": 621843, "averageVolume10days": 995230, "averageDailyVolume10Day": 995230, "bid": 1.36, "ask": 2.29, "bidSize": 2, "askSize": 2, "marketCap": 112872944, "fiftyTwoWeekLow": 0.833, "fiftyTwoWeekHigh": 5.39, "priceToSalesTrailing12Months": 40.025867, "fiftyDayAverage": 1.2803, "twoHundredDayAverage": 1.3026, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 43391004, "profitMargins": 0.0, "floatShares": 41180042, "sharesOutstanding": 62018100, "sharesShort": 4334176, "sharesShortPriorMonth": 4695721, "sharesShortPreviousMonthDate": 1753920000, "dateShortInterest": 1756425600, "sharesPercentSharesOut": 0.0699, "heldPercentInsiders": 0.23386, "heldPercentInstitutions": 0.3373, "shortRatio": 10.29, "shortPercentOfFloat": 0.0846, "impliedSharesOutstanding": 62018100, "bookValue": 1.413, "priceToBook": 1.2880397, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -96286000, "trailingEps": -1.59, "forwardEps": -1.19, "enterpriseToRevenue": 15.387, "enterpriseToEbitda": -0.539, "52WeekChange": -0.4958449, "SandP52WeekChange": 0.16885936, "quoteType": "EQUITY", "currentPrice": 1.82, "targetHighPrice": 8.0, "targetLowPrice": 5.0, "targetMeanPrice": 6.0, "targetMedianPrice": 5.5, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 6, "totalCash": 88944000, "totalCashPerShare": 1.434, "ebitda": -80537000, "totalDebt": 19462000, "quickRatio": 5.201, "currentRatio": 5.654, "totalRevenue": 2820000, "debtToEquity": 22.206, "revenuePerShare": 0.046, "returnOnAssets": -0.31252, "returnOnEquity": -0.74804, "grossProfits": 2820000, "freeCashflow": -42194624, "operatingCashflow": -73753000, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -6.76099, "financialCurrency": "USD", "symbol": "PYXS", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1633699800000, "regularMarketPrice": 1.82, "marketState": "CLOSED", "shortName": "Pyxis Oncology, Inc.", "longName": "Pyxis Oncology, Inc.", "exchange": "NMS", "messageBoardId": "finmb_629268721", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "postMarketChangePercent": 0.0604365, "postMarketPrice": 1.8211, "postMarketChange": 0.00109994, "regularMarketChange": -0.04, "regularMarketDayRange": "1.76 - 1.92", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 621843, "fiftyTwoWeekLowChange": 0.98700005, "fiftyTwoWeekLowChangePercent": 1.184874, "fiftyTwoWeekRange": "0.833 - 5.39", "fiftyTwoWeekHighChange": -3.5699997, "fiftyTwoWeekHighChangePercent": -0.6623376, "fiftyTwoWeekChangePercent": -49.58449, "earningsTimestampStart": 1762891200, "earningsTimestampEnd": 1762891200, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -1.59, "epsForward": -1.19, "epsCurrentYear": -1.28, "priceEpsCurrentYear": -1.4218751, "fiftyDayAverageChange": 0.53970003, "fiftyDayAverageChangePercent": 0.42154184, "twoHundredDayAverageChange": 0.5174, "twoHundredDayAverageChangePercent": 0.3972056, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-10-08", "averageAnalystRating": "1.5 - Strong Buy", "cryptoTradeable": false, "corporateActions": [], "postMarketTime": 1757716682, "regularMarketTime": 1757707200, "regularMarketChangePercent": -2.15054, "displayName": "Pyxis Oncology", "trailingPegRatio": null, "__fetch_time": "2025-09-13"}]